ADH-1 trifluoroacetate

SKU: orb1308039

Description

ADH-1 trifluoroacetate (Exherin) is a cyclic pentapeptide that selectively inhibits N-cadherin, disrupting tumor vasculature and inducing apoptosis. It is used in cancer research for its antiangiogenic properties, studied in both in vitro models and in vivo xenograft experiments targeting N-cadherin-expressing tumors.

Research Area

Signal Transduction

Images & Validation

−

Key Properties

−

CAS Number	1135237-88-5
MW	684.71
Purity	99.98% (May vary between batches)
Formula	C₂₄H₃₅F₃N₈O₈S₂
SMILES	OC(=O)C(F)(F)F.CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O
Target	Cadherin
Solubility	10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (2.92 mM);DMSO:43 mg/mL (62.8 mM)

Bioactivity

−

In Vivo	In a mouse model for pancreatic cancer, ADH-1 (50 mg/kg) markedly inhibits tumor growth and metastasis . In a rat aortic ring assay or antitumor potential in a PC3 subcutaneous xenograft tumor model, ADH-1 does not display either antiangiogenic activity . The augmentation of melanoma tumor growth mediated by ADH-1 is not altered by regionally infused temozolomide. In A375, but not DM443 xenografts, ADH-1 can increase phosphorylation of AKT at serine 473. ADH-1 slightly diminishes N-cadherin expression in both xenografts. Read more...
In Vitro	In pancreatic cancer cells, Exherin (0.2 mg/mL) blocks collagen I-mediated changes and is highly potent at preventing cell motility induced by expression of N-cadherin. Exherin (0-1.0 mg/mL) dose-dependently induces apoptosis in a N-cadherin-dependent manner. Read more...
Animal Research	Exherin is prepared in PBS.Animals are anesthetized, and 40 μL of a single cell suspension containing 50,000 cells is injected into the pancreas. Mice are randomized into treatment groups 10 days after surgery. For treatment, mice are injected intraperitoneally once per day with Exherin at 50 mg/kg in 100 μL PBS (×1 per day, ×5 per week for 4 weeks). For in vivo bioluminescence, D-Luciferin is administered by intraperitoneal injection. Data are acquired 20 min after injection using the IVIS system. Tumor growth is monitored every 10 days from day 10 to day 50 after surgery. Luciferase activity is quantified using the IVIS system. Two months after surgery, the mice are killed, and the pancreas, liver, lung, and disseminated nodules are harvested, fixed in 10% buffered formalin, and embedded in paraffin. Serial 5-μM sections are cut, mounted on slides, and stained with H&E using standard procedures. Read more...

Storage & Handling

−

Storage	keep away from moisture \| Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice/Shipping at ambient temperature.
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

ADH 1, ADH 1 Trifluoroacetate, ADH 1 trifluoroacetate, ADH1, ADH-1, ADH1 trifluoroacetate, ADH1 Trifluoroacetate, ADH-1 Trifluoroacetate, Exherin trifluoroacetate, Exherin Trifluoroacetate, Inhibitor, N-cadherin, inhibit

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Compound Identifiers

PubChem CID

24203776 ↗

Key Properties

−

No computed properties available.

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Find More Protocols